Ambry Genetics Market Research Report
Company Overview
Name: Ambry Genetics
Mission: Ambry Genetics is dedicated to providing high-quality, accessible genetic testing to enable healthcare professionals to make informed patient care decisions through advanced genetic testing solutions.
Founded: 1999 by Charles L.M. Dunlop
Key People:
- Tom Schoenherr - Chief Executive Officer
- Brigette Tippin Davis, PhD, FACMG - Chief Operating Officer
- Michael Martinson - Chief Financial Officer
- Elizabeth Chao, MD, FACMG - Chief Medical Officer
- Michelle Smith - General Counsel
- Mickie Henshall - Chief Marketing Officer
- Catherine Suh - SVP, People
- Mark Konopka - SVP, Sales
- Chia-Ling Gau, PhD, DABMG - VP, Global Head of Quality & Regulatory
- Donavan Cheng, PhD - VP, Analytic-Omics
Headquarters: Aliso Viejo, California, USA
Number of Employees: No information is available
Revenue: No information is available
Known For: Ambry Genetics is renowned for leading developments in genetic testing, especially in the fields of hereditary cancer and rare disease testing, leveraging Paired DNA/RNA testing, and innovative programs like the Ambry CARE Program®.
Products
Paired DNA/RNA Testing with +RNAinsight®
Aids in the detection and classification of DNA variants, particularly beneficial in identifying hereditary cancer.
Key Features:
- Analyzes functional RNA data
- Provides more positive results
- Resolves variants of uncertain significance
- Reduces evidence gaps in non-White populations
Exome Testing
Focused on rare diseases, this product includes ongoing proactive reanalysis through the Patient for Life program.
Key Features:
- Updated findings based on new gene-disease discoveries
- No additional cost for updated insights
Ambry CARE Program®
An end-to-end digital health solution designed for patient identification, education, and genetic testing facilitation.
Key Features:
- Identifies patients at risk for genetic conditions
- Supports patient education
- Enhances test ordering and results reporting
- Promotes proactive healthcare
Recent Developments
Acquisition by Tempus:
Tempus AI, Inc. completed the acquisition of Ambry Genetics in February 2025 for $375 million in cash and $225 million in shares. Ambry continues to operate as a subsidiary under current leadership.
New Products and Enhancements:
- Multiomic Exome Test: Announced in August 2024 for improved rare disease detection.
- Hereditary Cancer Test Menu: Introduced in September 2024, expanding the range of genetic tests offered.
Partnerships and Collaborations:
- Collaboration with Tempus to advance paired germline and somatic testing services.
- Partnership with PacBio to sequence up to 7,000 human genomes focused on rare diseases.
Research and Innovation:
- Contributed to a study published in Nature on BRCA2 gene variants, highlighting the use of CRISPR/cas-9 for functional characterization.
Please contact Ambry Genetics for more information about their comprehensive suite of solutions for hereditary cancer testing and other genetic offerings. Visit [www.ambrygen.com](http://www.ambrygen.com) for further details.
